Aakriti Aggarwal

Dr. Aakriti Aggarwal

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Journal of Minimally Invasive Gynecology
Verified
Journal Article
Closed access
AAAakriti Aggarwal
Aakriti Aggarwal
AHArchana Hatti
Archana Hatti
STSakunthala Sahithi Tirumuru
Sakunthala Sahithi Tirumuru
SNSabita Sivaraman Nair
Sabita Sivaraman Nair

2 September 2024 in Diseases
Verified
Journal Article
Open access
PDF file
AAAakriti Aggarwal
Aakriti Aggarwal
FFFederico Ferrari
Federico Ferrari
AZAndreas Zouridis
Andreas Zouridis
SKSean Kehoe
Sean Kehoe
SPSarah Pratap
Sarah Pratap
HMHooman Soleymani majd
Hooman Soleymani majd
Uterine sarcomas are rare and aggressive gynecological malignancies. We evaluated the epidemiology, treatment outcomes and survival rates in uterine sarcoma patients managed in our institute. The medical records of women with histology proven uterine sarcoma, including leiomyosarcoma (LMS), adenosarcoma (ADS), and endometrial stromal sarcoma (ESS), treated at our institution from February 2010 to February 2022, were analyzed. In total, 41 patients were identified. In detail, LMS, ADS, and high-grade and low-grade ESS were identified, respectively, in 60.9%, 19.5%, 12.1%, and 7.3% of the cases. The majority of women affected by LMS (72%) underwent primary surgery and 40% of them also received adjuvant chemotherapy. A surgical approach was the preferred mode of treatment in 83% of the recurrences. The median OS (overall survival), DFS (disease free survival), and PFS (progression free survival) for the LMS group were 25, 44.5, and 8 months, respectively. The 5-year survival rates for LMS, ADS, and ESS groups were 30.5%, 100% and 37.5%, respectively. The 5-year survival for LMS was found to be significantly worse than for other histology types (p = 0.016). Our study provides valuable data for the evaluation of treatment strategies and survival trends among these rare cancers. The management and follow-up planning of each subtype requires a thorough patient-focused multidisciplinary discussion.

28 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
CPChristina Pappa
Christina Pappa
AAAakriti Aggarwal
Aakriti Aggarwal
STSally El Tawab
Sally El Tawab
SNSabina Ioana Nistor
Sabina Ioana Nistor
JTJennifer Thorne
Jennifer Thorne
HMHooman Soleymani majd
Hooman Soleymani majd
Background/Objectives: To evaluate the clinicopathological features, treatment, and survival outcomes and to identify independent prognosticators for recurrence and mortality in patients with endometrioid ovarian cancer. Methods: The medical records of patients diagnosed with endometrioid ovarian carcinoma between January 2010 and December 2022 were reviewed retrospectively. Demographic and disease-related data were evaluated. Kaplan–Meier survival analysis using log rank test and Cox regression was performed. Results: Seventy-six patients were included in the study. The median age at diagnosis was 54 years (range 31–86). A total of 85.5% of the patients were diagnosed with early-stage disease and 88.1% of the tumours represented low-grade carcinomas. Synchronous endometrioid endometrial cancer was confirmed in 19.7% of the cases. All patients underwent surgical management and 65.8% received adjuvant chemotherapy. Median follow-up time was 67.5 months. The 5-year disease-free survival and overall survival were 92.1% and 93.4%, respectively. The risk of cancer-related death was higher in advanced stages (HR = 13.86; 95% CI 2.16–57.17; p < 0.001) and in the presence of residual disease (HR = 15.18; 95% CI 2.36–87.17; p < 0.002). Residual disease and advanced stages were also identified as independent risk factors for disease relapse with HR = 16.04 (95% CI 2.61–93.7; p < 0.002) and HR = 11.73 (95% CI 1.92–41.6; p < 0.001), respectively. Conclusions: Endometrioid ovarian carcinoma usually affects younger patients with the majority of the cases representing low-grade carcinomas diagnosed at early stages. Residual disease and advanced stages are independently associated with inferior survival outcomes. There was no significance of lymph node dissection and adjuvant chemotherapy in the overall and recurrence-free survival rates. Further research focusing on molecular profiling should aim to define the prevalence and the prognostic value of major molecular alterations and develop precise stratification models to plan personalised treatment for optimal care.

27 May 2025
Verified
Preprint
Open access
AAAakriti Aggarwal
Aakriti Aggarwal
PRPhillip Rolland
Phillip Rolland
ELElaine Leung
Elaine Leung
JMJo Morrison
Jo Morrison
JBJohn Butler
John Butler
HMHooman Soleymani Majd
Hooman Soleymani Majd

22 May 2026 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
PDF file
AAAakriti Aggarwal
Aakriti Aggarwal
PRPhilip Rolland
Philip Rolland
ELElaine Leung
Elaine Leung
JMJo Morrison
Jo Morrison
JBJohn Butler
John Butler
HMHooman Soleymani majd
Hooman Soleymani majd
Click on the article title to read more.

1 January 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
SSSarah Louise Smyth
Sarah Louise Smyth
AAAakriti Aggarwal
Aakriti Aggarwal
HMHooman Soleymani majd
Hooman Soleymani majd
Metastases to the lesser sac (also known as the omental bursa) and its contents are frequently seen in advanced ovarian cancer. This would require a thorough and meticulous intra-operative surgical exploration and mapping for patients requiring radical supracolic omentectomy requiring sacrifice of the gastro-epiploic arcade. We describe an educational surgical technique with maximum effort to preserve the right and left gastric arteries, when the right and left gastro-epiploic arteries and short gastric arteries are divided. These steps are demonstrated with attention to anatomical landmarks of the lesser sac to minimise intraoperative and postoperative morbidity. This surgical approach will not only spare the gastric branches of the vagus nerve (rami gastrici) but also prevent gastric ischaemic changes. We describe the case of a 77-year-old female patient diagnosed with stage 3C high grade serous ovarian/tubal cancer on the neoadjuvant chemotherapy pathway, undergoing delayed debulking surgery. The gynaecological oncology surgeon should confidently hold detailed knowledge of upper abdominal anatomy in their armamentarium, to maximise the safety and efficacy of ultra-radical surgery to achieve R0 (no residual disease); which is a single independent risk factor for survival. This video demonstrates a challenging case with an undesirable location of metastatic disease requiring advanced upper abdomen surgical skills and knowledge, with specific consideration of intraoperative multidisciplinary decision-making.